U.S. Markets open in 22 mins

Passage Bio, Inc. (PASG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.82-4.49 (-16.44%)
At close: 4:00PM EST

20.65 -2.17 (-9.51%)
Before hours: 9:08AM EST

Passage Bio, Inc.

Two Commerce Square
28th Floor 2001 Market Street
Philadelphia, PA 19103
United States
267 866 0311

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Bruce A. Goldsmith M.B.A., Ph.D.CEO, Pres & Director485.72kN/A1966
Dr. Stephen P. SquintoCo-Founder, Acting Head of R&D and Director786.99kN/A1956
Ms. Jill M. Quigley J.D.Chief Operating Officer756.38kN/A1976
Dr. Gary Romano M.D., Ph.D.Chief Medical Officer519.77kN/A1962
Dr. James M. Wilson M.D., Ph.D.Co-Founder & Chief Scientific AdvisorN/AN/A1955
Mr. Richard S. MorrisChief Financial OfficerN/AN/A1974
Mr. Alexandros Fotopoulos MSc, MBAChief Technical OfficerN/AN/A1969
Mr. Edgar B. Cale Esq., J.D.Gen. Counsel & Company Sec.N/AN/A1964
Robin DeRogatisVP HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Corporate Governance

Passage Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.